Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-31
2006-01-31
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S420000
Reexamination Certificate
active
06992100
ABSTRACT:
A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
REFERENCES:
patent: 4910218 (1990-03-01), Bair
patent: 4999369 (1991-03-01), Bair
patent: 5523297 (1996-06-01), Pruzanski et al.
patent: 6872743 (2005-03-01), Beight et al.
patent: 0 950 661 (1999-10-01), None
patent: WO 00/07590 (2000-02-01), None
Chemical Abstracts, vol. 124, No. 23 (1996); Columbus, Ohio, US; Abstract No. 317028x, p. 1205; XP002202619.
Beight Douglas Wade
Jandzinski John David
Kinnick Michael Dean
Lin Ho-Shen
Morin, Jr. John Michael
Eli Lilly and Company
Ginah Francis O.
Shameem Golam M. M.
LandOfFree
sPLA 2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with sPLA 2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and sPLA 2 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574290